Cargando…

Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid agonist therapy (OAT) is scarce. This study examined ADHD symptoms using the AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Vold, Jørn Henrik, Halmøy, Anne, Chalabianloo, Fatemeh, Pierron, Marianne Cook, Løberg, Else-Marie, Johansson, Kjell Arne, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308780/
https://www.ncbi.nlm.nih.gov/pubmed/37386438
http://dx.doi.org/10.1186/s12888-023-04980-w
_version_ 1785066319491629056
author Vold, Jørn Henrik
Halmøy, Anne
Chalabianloo, Fatemeh
Pierron, Marianne Cook
Løberg, Else-Marie
Johansson, Kjell Arne
Fadnes, Lars Thore
author_facet Vold, Jørn Henrik
Halmøy, Anne
Chalabianloo, Fatemeh
Pierron, Marianne Cook
Løberg, Else-Marie
Johansson, Kjell Arne
Fadnes, Lars Thore
author_sort Vold, Jørn Henrik
collection PubMed
description BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid agonist therapy (OAT) is scarce. This study examined ADHD symptoms using the ADHD self-report scale (ASRS) and the association between the ‘ASRS–memory’ and ‘ASRS–attention’ scores and substance use and sociodemographic characteristics among patients receiving OAT. METHODS: We used data from assessment visits of a cohort of patients in Norway. In total, 701 patients were included from May 2017 to March 2022. All patients responded at least once to two ASRS questions assessing memory and attention, respectively. Ordinal regression analyses were performed to investigate whether the two obtained scores were associated with age, sex, frequent substance use, injecting use, housing status, and educational attainment at baseline, i.e., the first assessment, and over time. The results are presented as odds ratios (OR) with 95% confidence intervals (CI). Additionally, a subsample of 225 patients completed an extended interview, including the ASRS–screener and collection of registered mental disorder diagnoses from the medical records. Standard cutoffs were used to define the presence of each ASRS symptom or a positive ASRS–screener (‘ASRS–positive’). RESULTS: At baseline, 428 (61%) and 307 (53%) patients scored over the cutoffs on the ‘ASRS–memory’ and ‘ASRS–attention,’ respectively. Frequent cannabis use was associated with higher ‘ASRS–memory’ (OR: 1.7, 95% CI: 1.1–2.6) and ‘ASRS–attention’ (1.7, 1.1–2.5) scores compared with less or no use at baseline, though reduced score on the ‘ASRS–memory’ over time (0.7, 0.6–1.0). At baseline, frequent stimulant use (1.8, 1.0–3.2) and low educational attainment (0.1, 0.0–0.8) were associated with higher ‘ASRS–memory’ scores. In the subsample fulfilling the ASRS–screener, 45% of the patients were ‘ASRS–positive,’ of whom 13% with a registered ADHD diagnosis. CONCLUSIONS: Our findings illustrate a relationship between the ASRS–memory and –attention scores and frequent cannabis and stimulant use. Furthermore, nearly half of the subsample was ‘ASRS–positive.’ Patients receiving OAT might benefit from being further assessed for ADHD, but improved diagnostic methods are required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04980-w.
format Online
Article
Text
id pubmed-10308780
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103087802023-06-30 Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study Vold, Jørn Henrik Halmøy, Anne Chalabianloo, Fatemeh Pierron, Marianne Cook Løberg, Else-Marie Johansson, Kjell Arne Fadnes, Lars Thore BMC Psychiatry Research BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid agonist therapy (OAT) is scarce. This study examined ADHD symptoms using the ADHD self-report scale (ASRS) and the association between the ‘ASRS–memory’ and ‘ASRS–attention’ scores and substance use and sociodemographic characteristics among patients receiving OAT. METHODS: We used data from assessment visits of a cohort of patients in Norway. In total, 701 patients were included from May 2017 to March 2022. All patients responded at least once to two ASRS questions assessing memory and attention, respectively. Ordinal regression analyses were performed to investigate whether the two obtained scores were associated with age, sex, frequent substance use, injecting use, housing status, and educational attainment at baseline, i.e., the first assessment, and over time. The results are presented as odds ratios (OR) with 95% confidence intervals (CI). Additionally, a subsample of 225 patients completed an extended interview, including the ASRS–screener and collection of registered mental disorder diagnoses from the medical records. Standard cutoffs were used to define the presence of each ASRS symptom or a positive ASRS–screener (‘ASRS–positive’). RESULTS: At baseline, 428 (61%) and 307 (53%) patients scored over the cutoffs on the ‘ASRS–memory’ and ‘ASRS–attention,’ respectively. Frequent cannabis use was associated with higher ‘ASRS–memory’ (OR: 1.7, 95% CI: 1.1–2.6) and ‘ASRS–attention’ (1.7, 1.1–2.5) scores compared with less or no use at baseline, though reduced score on the ‘ASRS–memory’ over time (0.7, 0.6–1.0). At baseline, frequent stimulant use (1.8, 1.0–3.2) and low educational attainment (0.1, 0.0–0.8) were associated with higher ‘ASRS–memory’ scores. In the subsample fulfilling the ASRS–screener, 45% of the patients were ‘ASRS–positive,’ of whom 13% with a registered ADHD diagnosis. CONCLUSIONS: Our findings illustrate a relationship between the ASRS–memory and –attention scores and frequent cannabis and stimulant use. Furthermore, nearly half of the subsample was ‘ASRS–positive.’ Patients receiving OAT might benefit from being further assessed for ADHD, but improved diagnostic methods are required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04980-w. BioMed Central 2023-06-29 /pmc/articles/PMC10308780/ /pubmed/37386438 http://dx.doi.org/10.1186/s12888-023-04980-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vold, Jørn Henrik
Halmøy, Anne
Chalabianloo, Fatemeh
Pierron, Marianne Cook
Løberg, Else-Marie
Johansson, Kjell Arne
Fadnes, Lars Thore
Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
title Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
title_full Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
title_fullStr Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
title_full_unstemmed Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
title_short Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
title_sort attention-deficit/hyperactivity disorder (adhd) symptoms and their relation to diagnosed adhd, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a norwegian cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308780/
https://www.ncbi.nlm.nih.gov/pubmed/37386438
http://dx.doi.org/10.1186/s12888-023-04980-w
work_keys_str_mv AT voldjørnhenrik attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy
AT halmøyanne attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy
AT chalabianloofatemeh attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy
AT pierronmariannecook attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy
AT løbergelsemarie attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy
AT johanssonkjellarne attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy
AT fadneslarsthore attentiondeficithyperactivitydisorderadhdsymptomsandtheirrelationtodiagnosedadhdsociodemographiccharacteristicsandsubstanceuseamongpatientsreceivingopioidagonisttherapyanorwegiancohortstudy